var data={"title":"Zolpidem: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Zolpidem: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7185?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=zolpidem-patient-drug-information\" class=\"drug drug_patient\">see &quot;Zolpidem: Patient drug information&quot;</a> and <a href=\"topic.htm?path=zolpidem-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Zolpidem: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236158\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ambien;</li>\n      <li>Ambien CR;</li>\n      <li>Edluar;</li>\n      <li>Intermezzo;</li>\n      <li>Zolpimist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13452765\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sublinox</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236195\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Hypnotic, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236162\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Insomnia:</b> Oral: <b>Note:</b> The lowest effective dose should be used; higher doses may be more likely to impair next morning activities. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release tablet, spray: 5 mg (females) or 5 to 10 mg (males) immediately before bedtime; maximum dose: 10 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablet: 6.25 mg (females) or 6.25 to 12.5 mg (males) immediately before bedtime; maximum dose: 12.5 mg daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Edluar, Sublinox [Canadian product]: 5 mg (females) or 5 to 10 mg (males) immediately before bedtime; if 5 mg dose is ineffective may increase to 10 mg (maximum dose: 10 mg daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermezzo: <b>Note:</b> Take in bed only if &ge;4 hours left before waking and there is difficulty in returning to sleep</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Females: 1.75 mg once per night as needed (maximum: 1.75 mg/night)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Males: 3.5 mg once per night as needed (maximum: 3.5 mg/night)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment with concomitant CNS depressants:</i> Females and males: 1.75 mg once per night as needed; dose adjustment of concomitant CNS depressant(s) may be necessary.</p>\n    <p style=\"text-indent:0em;\">Debilitated:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release tablet, spray: 5 mg immediately before bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublingual tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Edluar, Sublinox [Canadian product]: 5 mg immediately before bedtime </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release tablet: 6.25 mg immediately before bedtime</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236163\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release tablet, spray: 5 mg immediately before bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Edluar, Sublinox [Canadian product]: 5 mg immediately before bedtime </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermezzo: Females and males: 1.75 mg once per night as needed (maximum: 1.75 mg/night). <b>Note:</b> Take in bed only if &ge;4 hours left before waking and there is difficulty in returning to sleep.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablet: 6.25 mg immediately before bedtime</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236164\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not dialyzable</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236165\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: 5 mg immediately before bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Avoid use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: 6.25 mg immediately before bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Avoid use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral spray: 5 mg immediately before bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Edluar: 5 mg immediately before bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermezzo: Females and males: 1.75 mg once per night as needed. <b>Note:</b> Take in bed only if &ge;4 hours left before waking and there is difficulty in returning to sleep.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublinox [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate impairment: 5 mg immediately before bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236134\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as tartrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zolpimist: 5 mg/actuation (4.5 mL, 7.7 mL) [contains benzoic acid, propylene glycol; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as tartrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ambien: 5 mg [contains fd&amp;c red #40, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ambien: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral, as tartrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ambien CR: 6.25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ambien CR: 12.5 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6.25 mg, 12.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Sublingual, Sublingual, as tartrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Edluar: 5 mg, 10 mg [contains saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermezzo: 1.75 mg, 3.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1.75 mg, 3.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236119\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13456321\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Sublingual, as tartrate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sublinox: 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236197\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-IV</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874935\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ambien: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019908s037lbl.pdf#page=22&amp;token=75PsuI+EeUfWlTrJ3gqZANsudOS1cZr8VexmYVuGbVYh8QTVEdj8UN/KrRzFqcRpxQHCUHPr7P+cP1uYdpcrqn/pprBteWVqLa2gv8bG3nooxeb8F38uRkf5NO8LzLxm&amp;TOPIC_ID=10057\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019908s037lbl.pdf#page=22</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ambien CR: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021774s018lbl.pdf#page=24&amp;token=CKPde+Cmbyo2vs9FV6Wx1xkZekKqJ7gTI7vP3Ph2HTnaOGqlT7sHW+8wFX9pI0cQbd9H9eVkxEQT8XLjoOVQ8fua+NbnNB9R7fBXykLqB2DdA0xlu2mU3lsWilG47lku&amp;TOPIC_ID=10057\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021774s018lbl.pdf#page=24</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Edluar: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM135937.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQiFnDZrbs/BGuJiptmuAjeg==&amp;TOPIC_ID=10057\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM135937.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermezzo: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM281854.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68KmduXd4oyjZ9b8vE0MZPow==&amp;TOPIC_ID=10057\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM281854.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zolpidem:<a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089833.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRl12ZIlF2tdv36w+uFduP1bw==&amp;TOPIC_ID=10057\" target=\"_blank\"> http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089833.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zolpimist: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM143465.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQKahWXH8nO1Kzm8YzUkQrQw==&amp;TOPIC_ID=10057\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM143465.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236139\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer immediately before bedtime due to rapid onset of action. Regardless of dosage form, do not administer with or immediately after a meal (may delay onset). With the exception of Intermezzo, zolpidem should be taken as a single dose and should not be readministered during the same night. Intermezzo should be taken in bed if patient awakes in the middle of the night (ie, if &ge;4 hours left before waking) and there is difficulty in returning to sleep.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablet: Swallow tablet whole; do not divide, crush, or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablet: Place sublingual tablet under the tongue and allow to disintegrate; do not swallow or administer Edluar or Sublinox with water.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral spray: Spray directly into the mouth over the tongue. Prior to initial use, prime pump by spraying 5 times. If pump is not used for at least 14 days, reprime pump with 1 spray.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236138\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Insomnia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release and sublingual tablets (Edluar only) and oral spray: Short-term treatment of insomnia with difficulty of sleep onset</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablet: Treatment of insomnia with difficulty of sleep onset and/or sleep maintenance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablet (Intermezzo only): &quot;As needed&quot; treatment of insomnia when middle-of-the-night awakening is followed by difficulty returning to sleep and the patient has &ge;4 hours of sleep time remaining</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablet (Sublinox only [Canadian product]): Short-term treatment of insomnia (with difficulty of sleep onset, frequent awakenings, and/or early awakenings)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236204\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ambien may be confused with Abilify, Ativan, Ambi 10</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Sublinox may be confused with Suboxone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zolpidem may be confused with lorazepam, zaleplon, Zyloprim</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Zolpidem, a nonbenzodiazepine benzodiazepine-receptor agonist hypnotic, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to adverse events similar to benzodiazepines in older adults (eg, delirium, falls, fractures) and an increase in emergency room visits, hospitalizations, and motor vehicle crashes. In addition, improvement in sleep latency and duration is minimal (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Zolpidem (when cumulative day supply is &gt;90 days) is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ambien [US, Argentina, Israel] may be confused with Amyben brand name for amiodarone [Great Britain]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236126\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported with oral administration, unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Headache (oral: 7% to 19%; sublingual: 3%), drowsiness (2% to 15%), dizziness (1%  to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Palpitations (2%), chest discomfort (1%), chest pain (1%), increased blood pressure (1%), edema (&le;1%), hypertension (&le;1%), orthostatic hypotension (&le;1%), syncope (&le;1%), tachycardia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (2% to 6%), hallucination (&le;4%), disorientation (3%), drugged feeling (3%), fatigue (oral: 3%; sublingual: 1%), lethargy (3%), memory impairment (3%), equilibrium disturbance (2%), psychomotor retardation (2%), vertigo (2%), hypoesthesia (&le;2%), lack of concentration (&le;2%), depression (2%), confusion (&gt;1%), insomnia (&gt;1%), abnormal dreams (1%), amnesia (1%), ataxia (1%), disinhibition (1%), eating disorder (1%; binge eating), euphoria (1%), increased body temperature (1%), sleep disorder (1%), stress (1%), agitation (&le;1%), apathy (&le;1%), cerebrovascular disease (&le;1%), cognitive dysfunction (&le;1%), depersonalization (&le;1%), dysarthria (&le;1%), emotional lability (&le;1%), falling (&le;1%), illusion (&le;1%), malaise (&le;1%), migraine (&le;1%), nervousness (&le;1%), paresthesia (&le;1%), speech disturbance (&le;1%), stupor (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (1% to 2%), diaphoresis (&le;1%), pallor (&le;1%), pruritus (&le;1%), urticaria (&le;1%), wrinkling of skin (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypermenorrhea (1%), hyperglycemia (&le;1%), increased thirst (&le;1%), menstrual disease (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (7%), xerostomia (3%), diarrhea (1% to 3%), constipation (2%), dyspepsia (&gt;1%), hiccups (&gt;1%), abdominal distress (1%), abdominal tenderness (1%), change in appetite (1%), frequent bowel movements (1%), gastroesophageal reflux disease (1%), anorexia (&le;1%), dysgeusia (&le;1%), flatulence (&le;1%), gastroenteritis (&le;1%), vomiting (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (&gt;1%), cystitis (&le;1%), dysuria (&le;1%), urinary incontinence (&le;1%), vaginitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (&le;1%), increased serum ALT (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (3%), infection (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (4%), back pain (3% to 4%), neck pain (2%), arthralgia (&gt;1%), weakness (1%), arthritis (&le;1%), leg cramps (&le;1%), tremor (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (1% to 3%; including altered depth perception), blurred vision (2%), eye redness (2%), diplopia (&gt;1%), asthenopia (1%), eye irritation (&le;1%), eye pain (&le;1%), scleritis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Labyrinthitis (1%), tinnitus (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Sinusitis (4%), pharyngitis (3%), flu-like symptoms (1% to 2%), lower respiratory tract infection (&gt;1%), upper respiratory tract infection (&gt;1%), throat irritation (1%), bronchitis (&le;1%), cough (&le;1%), dyspnea (&le;1%), rhinitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&le;1%), trauma (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, abnormal lacrimation, abnormality in thinking, abscess, accommodation disturbance, acne vulgaris, acute renal failure, aggressive behavior, alteration of saliva, altered sense of smell, anaphylactic shock, anaphylaxis, anemia, angina pectoris, angioedema (including tongue, glottis, larynx), arteritis, behavioral changes, breast fibroadenosis, breast neoplasm, bronchospasm, bullous rash, cardiac arrhythmia, circulatory shock, conjunctivitis, corneal ulcer, decreased libido, delusions, dementia, dental caries, dermatitis, drug tolerance, dysphagia, dysphasia, enteritis, epistaxis, eructation, esophageal spasm, exacerbation of hypertension, extrasystoles, facial edema, furunculosis, gastritis, glaucoma, gout, hemorrhoids, hepatic encephalopathy (in patients with hepatic insufficiency), hepatitis (mixed pattern, hepatocellular, and cholestatic; with or without jaundice), herpes simplex infection, herpes zoster, hot flash, hyperbilirubinemia, hypercholesteremia, hyperhemoglobinemia, hyperlipidemia, hypokinesia, hypotension, hypotonia, hypoxia, hysteria, impotence, increased appetite, increased blood urea nitrogen, increased erythrocyte sedimentation rate, increased serum alkaline phosphatase, increased serum AST, inflammation at injection site, intestinal obstruction, intoxicated feeling, laryngitis, leukopenia, lymphadenopathy, macrocytic anemia, manic reaction, mastalgia, myasthenia, myocardial infarction, neuralgia, neuritis, neuropathy, nocturia, numbness of tongue, oral bullae (sublingual tablet), oral inflammation (sublingual tablet), oral mucosa ulcer (sublingual tablet), osteoarthritis, pain, otitis externa, otitis media, panic disorder, paresis, periorbital edema, personality disorder, phlebitis, photopsia, pneumonia, polyuria, psychoneurosis, pulmonary edema, pulmonary embolism, purpura, pyelonephritis, rectal hemorrhage, renal pain, respiratory depression, restless leg syndrome, rigors, sciatica, skin photosensitivity, sleep driving, somnambulism, strange feeling, suicidal ideation, suicidal tendencies, tendonitis, tenesmus, tetany, thrombosis, urinary frequency, urinary retention, varicose veins, ventricular tachycardia, weight loss, yawning</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236142\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to zolpidem or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Significant obstructive sleep apnea syndrome and acute and/or severe impairment of respiratory function; myasthenia gravis; severe hepatic impairment; personal or family history of sleepwalking</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236123\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abnormal thinking/behavioral changes: Hypnotics/sedatives have been associated with abnormal thinking and behavior changes including decreased inhibition (eg, aggressiveness and extroversion that seemed out of character), bizarre behavior, agitation, visual and auditory hallucinations, and depersonalization. These changes may occur unpredictably and may indicate previously unrecognized psychiatric disorders; evaluate appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression impairing physical and mental capabilities; patients must be cautioned about performing tasks which require mental alertness (operating machinery or driving). An increased risk of next-day psychomotor impairment is increased if patient is unable to stay in bed for a full night of sleep (7 to 8 hours); if coadministered with other CNS depressants and/or taken with other drugs that increase blood levels of zolpidem; or if a higher than recommended dose is taken. Dose adjustment may be necessary if taking concomitant CNS depressants; use with alcohol is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis as well as angioedema, have been reported after taking the first or subsequent doses. Do not rechallenge patient if such reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving, preparing and eating food, making phone calls, or having sex while asleep have also been noted; amnesia, anxiety, and other neuropsychiatric symptoms may also occur. Patients usually do not remember these events. The use of alcohol, other CNS depressants, and exceeding the recommended maximum dose may increase the risk of these activities. Discontinue treatment in patients who report any sleep-driving episodes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Use with caution in patients with depression; worsening of depression, including suicide or suicidal ideation has been reported with the use of hypnotics. Intentional overdose may be an issue in this population. The minimum dose that will effectively treat the individual patient should be used. Prescriptions should be written for the smallest quantity consistent with good patient care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug abuse: Use with caution in patients with a history of drug dependence. Risk of abuse is increased in patients with a history or family history of alcohol or drug abuse or mental illness.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: GABA agonists, including zolpidem, have been associated with precipitation of hepatic encephalopathy in patients with hepatic impairment. Patients with hepatic impairment do not clear zolpidem as rapidly as patients with normal hepatic function. Use with caution in patients with mild to moderate hepatic impairment; dose adjustment recommended. Avoid use of immediate and extended-release tablets in patients with severe hepatic impairment; may result in encephalopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory compromise, COPD, or sleep apnea.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated: Use with caution in debilitated patients; potential for oversedation, impaired coordination, and confusion with use; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; dose adjustment recommended. Monitor for impaired cognitive and/or motor performance, confusion, and potential for falling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Females: Dosage adjustment is recommended for females; pharmacokinetic studies involving zolpidem showed a significant increase in maximum concentration and exposure in females compared to males at the same dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: When studied for the unapproved use of insomnia associated with ADHD in children, a higher incidence (~7%) of hallucinations was reported. In addition, sleep latency did not decrease compared to placebo.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens).  Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Symptomatic treatment of insomnia should be initiated only after careful evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7 to 10 days may indicate the need for psychiatric and/or medical illness reevaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rapid onset: Because of the rapid onset of action, administer Intermezzo immediately prior to bedtime, after the patient has gone to bed and is having difficulty falling asleep, or during the middle of the night when at least 4 hours are left before waking.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Abrupt discontinuance or rapid dose decrease may lead to withdrawal symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236189\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236128\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10057&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Zolpidem may enhance the CNS depressant effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Zolpidem.  Management: Monitor zolpidem response closely.  Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving carbamazepine.  No such dose change is recommended for women.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Zolpidem. Management: Consider avoiding the combination of ciprofloxacin and zolpidem if possible. If combined, monitor for signs of zolpidem toxicity (eg, somnolence, dizziness, lethargy).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flumazenil: May diminish the sedative effect of Hypnotics (Nonbenzodiazepine).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May enhance the CNS depressant effect of Zolpidem. FluvoxaMINE may increase the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Zolpidem. Management: Consider using a lower starting dose of zolpidem in patients receiving ketoconazole and monitor for increased zolpidem effects/toxicities if these agents are combined.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May enhance the sedative effect of Hypnotics (Nonbenzodiazepine).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Zolpidem.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: Hypnotics (Nonbenzodiazepine) may enhance the CNS depressant effect of Sodium Oxybate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Zolpidem.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May decrease the serum concentration of Zolpidem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236154\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Maximum plasma concentration and bioavailability are decreased with food; time to peak plasma concentration is increased; half-life remains unchanged. Grapefruit juice may decrease the metabolism of zolpidem. Management: Do not administer with (or immediately after) a meal. Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236129\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1615032\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Zolpidem crosses the placenta (Juric, 2009). Severe neonatal respiratory depression has been reported when zolpidem was used at the end of pregnancy, especially when used concurrently with other CNS depressants. Children born of mothers taking sedative/hypnotics may be at risk for withdrawal; neonatal flaccidity has been reported in infants following maternal use of sedative/hypnotics during pregnancy. Additional adverse effects to the fetus/newborn have been noted in some studies (Wang, 2010; Wikner, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F18881628\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Zolpidem is present in breast milk (Pons 1989).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A single oral dose of immediate release zolpidem 20 mg was administered to 5 breastfeeding women; the amount of zolpidem recovered in milk samples 3 hours postadministration ranged from 0.76 to 3.88 mcg (0.004% to 0.019% of the administered maternal dose). Zolpidem was undetectable at 13 and 16 hours postadministration in all women (Pons 1989).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer recommends that caution be exercised when administering zolpidem to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1615035\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Do not administer with or immediately after a meal (may delay onset).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236131\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Daytime alertness; fall risk, respiratory rate (patients with compromised respiration); behavior profile; tolerance, abuse, and dependence; reevaluate if insomnia persists after 7 to 10 days of use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236122\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Zolpidem, an imidazopyridine hypnotic that is structurally dissimilar to benzodiazepines, enhances the activity of the inhibitory neurotransmitter, &gamma;-aminobutyric acid (GABA), via selective agonism at the benzodiazepine-1 (BZ<sub>1</sub>) receptor; the result is increased chloride conductance, neuronal hyperpolarization, inhibition of the action potential, and a decrease in neuronal excitability leading to sedative and hypnotic effects. Because of its selectivity for the BZ<sub>1</sub> receptor site over the BZ<sub>2</sub> receptor site, zolpidem exhibits minimal anxiolytic, myorelaxant, and anticonvulsant properties (effects largely attributed to agonism at the BZ<sub>2</sub> receptor site). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236141\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Immediate release: 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Immediate release: 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: C<sub>max</sub> and AUC is increased by ~45% in females compared to male subjects</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release and sublingual: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Biphasic absorption; rapid initial absorption (similar to immediate release product); then provides extended concentrations in the plasma beyond 3 hours postadministration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: 1.8 &plusmn; 0.8 L/kg (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;6 to 12 years: 2.2 &plusmn; 1.7 L/kg (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: 1.2 &plusmn; 0.4 L/kg (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.54 L/kg after an IV dose (Holm 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~93%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic methylation and hydroxylation via CYP3A4 (~60%), CYP2C9 (~22%), CYP1A2 (~14%), CYP2D6 (~3%), and CYP2C19 (~3%) to 3 inactive metabolites (Holm 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Immediate release: 70% (Holm 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: Immediate release: 1.8 hours (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;6 years and Adolescents: Immediate release: 2.3 hours (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release, Extended release: ~2.5 hours (range: 1.4 to 4.5 hours); Cirrhosis: Up to 9.9 hours; Elderly: Prolonged up to 32%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Spray: ~3 hours (range: 1.7 to 8.4)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sublingual tablet: ~3 hours (range: 1.4 to 6.7 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: Immediate release: 0.9 hours (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;6 to 12 years: Immediate release: 1.1 hours (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Immediate release: 1.3 hours (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: 1.6 hours; 2.2 hours with food</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: 1.5 hours; 4 hours with food</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Spray: ~0.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sublingual tablet: Edluar: ~1.4 hours, ~1.8 hours with food; Intermezzo: 0.6 to 1.3 hours, ~3 hours with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (48% to 67%, primarily as metabolites); feces (29% to 42%, primarily as metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance, apparent:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to 6 years: 11.7 &plusmn; 7.9 mL/minute/kg (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;6 to 12 years: 9.7 &plusmn; 10.3 mL/minute/kg (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: 4.8 &plusmn; 2 mL/minute/kg (Blumer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Intermezzo: Males: 4 mL/minute/kg; Females: 2.7 mL/minute/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236145\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zolpimist Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/ACT (4.5 mL): $49.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Edluar Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $445.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $445.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Intermezzo Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.75 mg (30): $446.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.5 mg (30): $446.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Sublingual</b> (Zolpidem Tartrate Sublingual)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.75 mg (30): $301.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.5 mg (30): $301.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Ambien CR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.25 mg (100): $2,020.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (100): $2,020.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Zolpidem Tartrate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.25 mg (100): $611.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (100): $611.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ambien Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $2,020.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $2,020.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zolpidem Tartrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $462.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $462.48</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F236146\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adorma (UA);</li>\n      <li>Adormix (CL);</li>\n      <li>Ambien (BB, BM, BS, BZ, GY, JM, PR, SR, TT);</li>\n      <li>Ambien CR (AR, IL);</li>\n      <li>Ambulax-2 (IN);</li>\n      <li>Conyx (KR);</li>\n      <li>Dalparan (ES);</li>\n      <li>Dormeben (CO);</li>\n      <li>Dormizol (AU);</li>\n      <li>Flazinil (EC);</li>\n      <li>Fulsadem (AR);</li>\n      <li>Hypnogen (EE);</li>\n      <li>Ivadal (AT);</li>\n      <li>Jonfa (VN);</li>\n      <li>Lioram (BR);</li>\n      <li>Nidraj (BD);</li>\n      <li>Niotal (IT);</li>\n      <li>Nitrest (BD, IN);</li>\n      <li>Nocte (CR, DO, GT, HN, LK, NI, PA, SV);</li>\n      <li>Nocte Sublingual (AR);</li>\n      <li>Nuo Bin (CN);</li>\n      <li>Nytamel (IE);</li>\n      <li>Sanval (RU);</li>\n      <li>Sleepman (TW);</li>\n      <li>Somidem (AU, MY);</li>\n      <li>Somit (AR, PY, UY);</li>\n      <li>Somnil (CO);</li>\n      <li>Somno (PE);</li>\n      <li>Sove (LK);</li>\n      <li>Stildem (AU);</li>\n      <li>Stilnix (IL);</li>\n      <li>Stilnoct (BE, DK, FI, GB, IE, IS, LU, NL, NO, SE);</li>\n      <li>Stilnox (AU, BF, BG, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DO, EE, ES, ET, FR, GH, GM, GN, GR, GT, HK, HN, HU, ID, IT, JO, KE, KR, KW, LB, LR, LT, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, PA, PE, PH, PK, PL, PT, PY, QA, RO, SA, SC, SD, SK, SL, SN, SV, TN, TR, TW, TZ, UG, VE, VN, ZA, ZM, ZW);</li>\n      <li>Stilnox CR (AU, BR, CO, CR, DO, GT, HK, HN, KR, MY, NI, PA, SG, SV);</li>\n      <li>Sucedal (EC);</li>\n      <li>Vicknox (HK);</li>\n      <li>Ziohex (PH);</li>\n      <li>Zodenox (MY);</li>\n      <li>Zodorm (IL);</li>\n      <li>Zoldem (AT, BD, DE, IE);</li>\n      <li>Zoldox (TW);</li>\n      <li>Zoliprex (LK);</li>\n      <li>Zolmia (ID);</li>\n      <li>Zolnod (IE);</li>\n      <li>Zolnox (PY, UY);</li>\n      <li>Zolpibell (AU);</li>\n      <li>Zolpicin (TW);</li>\n      <li>Zolpid (BD, KR);</li>\n      <li>Zolpinox (DE);</li>\n      <li>Zolpirest (PH);</li>\n      <li>Zolpitop (BE);</li>\n      <li>Zolsana (BG);</li>\n      <li>Zopidem (TW);</li>\n      <li>Zopim (MY, TW);</li>\n      <li>Zorimin (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity.<i> Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ambien (zolpidem tartrate tablet) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ambien CR (zolpidem tartrate tablet) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer JL, Reed MD, Steinberg F, et al, &quot;Potential Pharmacokinetic Basis for Zolpidem Dosing in Children With Sleep Difficulties,&quot; <i>Clin Pharmacol Ther</i>, 2008, 83(4):551-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/17957186/pubmed\" target=\"_blank\" id=\"17957186\">17957186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durand A, Th&eacute;not JP, Bianchetti G, et al, &ldquo;Comparative Pharmacokinetic Profile of Two Imidazopyridine Drugs: Zolpidem and Alpidem,&rdquo; <i>Drug Metab Rev</i>, 1992, 24(2):239-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/1576937/pubmed\" target=\"_blank\" id=\"1576937\">1576937</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edluar (zolpidem tartrate tablet) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holm KJ and Goa KL, &ldquo;Zolpidem: An Update of Its Pharmacology, Therapeutic Efficacy and Tolerability in the Treatment of Insomnia,&rdquo; <i>Drugs</i>, 2000, 59(4):865-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/10804040/pubmed\" target=\"_blank\" id=\"10804040\">10804040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Intermezzo (zolpidem tartrate tablet) [prescribing information]. Stamford, CT: Purdue Pharma; July 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juric S, Newport DJ, Ritchie JC, et al, &quot;Zolpidem (Ambien) in Pregnancy: Placental Passage and Outcome,&quot; <i>Arch Womens Ment Health</i>, 2009, 12(6):441-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/19657707/pubmed\" target=\"_blank\" id=\"19657707\">19657707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lange CL, &ldquo;Medication-Associated Somnambulism,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 2005, 44(3):211-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/15725964/pubmed\" target=\"_blank\" id=\"15725964\">15725964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Langtry HD and Benfield P, &ldquo;Zolpidem: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential,&rdquo; <i>Drugs</i>, 1990, 40(2):291-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/2226217/pubmed\" target=\"_blank\" id=\"2226217\">2226217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salva P and Costa J, &ldquo;Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem. Therapeutic Implications,&rdquo; <i>Clin Pharmacokinet</i>, 1995, 29(3):142-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/8521677/pubmed\" target=\"_blank\" id=\"8521677\">8521677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanger DJ, &ldquo;The Pharmacology and Mechanisms of Action of New Generation, Non-Benzodiazepine Hypnotic Agents,&rdquo; <i>CNS Drugs</i>, 2004, 18 (Suppl 1):9-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/15291009/pubmed\" target=\"_blank\" id=\"15291009\">15291009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity.<i> Lancet</i>. 1995;345(8960):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sublinox (zolpidem) [product monograph]. Laval, Quebec, Canada: Meda Valeant Pharma Canada Inc; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor JR, Vazquez CM, and Campbell KM, &ldquo;Pharmacologic Management of Chronic Insomnia,&rdquo; <i>South Med J</i>, 2006, 99(12):1373-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/17233194/pubmed\" target=\"_blank\" id=\"17233194\">17233194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang LH, Lin HC, Lin CC, et al, &quot;Increased Risk of Adverse Pregnancy Outcomes in Women Receiving Zolpidem During Pregnancy,&quot; <i>Clin Pharmacol Ther</i>, 2010, 88(3):369-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/20686480/pubmed\" target=\"_blank\" id=\"20686480\">20686480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wikner BN and K&auml;ll&eacute;n B, &quot;Are Hypnotic Benzodiazepine Receptor Agonists Teratogenic in Humans?&quot; <i>J Clin Psychopharmacol</i>, 2011, 31(3):356-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/zolpidem-drug-information/abstract-text/21508851/pubmed\" target=\"_blank\" id=\"21508851\">21508851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zolpimist oral spray (zolpidem tartrate) [prescribing information]. Louisville, KY: MAGNA Pharmaceuticals; February 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10057 Version 252.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F236158\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13452765\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F236195\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F236162\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F236163\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F236164\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F236165\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F236134\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F236119\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F13456321\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F236197\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874935\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F236139\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F236138\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F236204\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F236126\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F236142\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F236123\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F236189\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F236128\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F236154\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F236129\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1615032\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F18881628\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F1615035\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F236131\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F236122\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F236141\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F236145\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F236146\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10057|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=zolpidem-patient-drug-information\" class=\"drug drug_patient\">Zolpidem: Patient drug information</a></li><li><a href=\"topic.htm?path=zolpidem-pediatric-drug-information\" class=\"drug drug_pediatric\">Zolpidem: Pediatric drug information</a></li></ul></div></div>","javascript":null}